Researcher Portfolio

 
   

Malpartida, Ana Belen

IMPRS-BI: LMU, Munich, Seewiesen, Max Planck Institute for Biological Intelligence, Max Planck Society  

 

Researcher Profile

 
Position: IMPRS-BI: LMU, Munich, Seewiesen, Max Planck Institute for Biological Intelligence, Max Planck Society
Researcher ID: https://pure.mpg.de/cone/persons/resource/persons297491

External references

 
WorldCat Search for Malpartida, Ana Belen
Google Scholar Search for Malpartida, Ana Belen

Publications

 
 
 : Sonsalla, G., Malpartida, A. B., Riedemann, T., Gusic, M., Rusha, E., Bulli, G., Najas, S., Janjic, A., Hersbach, B. A., Smialowski, P., Drukker, M., Enard, W., Prehn, J. H. M., Prokisch, H., Gotz, M., & Masserdotti, G. (2024). Direct neuronal reprogramming of NDUFS4 patient cells identifies the unfolded protein response as a novel general reprogramming hurdle. Neuron, 2(7), 1117-1132.e9. doi:10.1016/j.neuron.2023.12.020. [PubMan] : Winchester, L., Barber, I., Lawton, M., Ash, J., Liu, B., Evetts, S., Hopkins-Jones, L., Lewis, S., Bresner, C., Malpartida, A. B., Williams, N., Gentlemen, S., Wade-Martins, R., Ryan, B., Holgado-Nevado, A., Hu, M., Ben-Shlomo, Y., Grosset, D., & Lovestone, S. (2022). Identification of a possible proteomic biomarker in Parkinson's disease: Discovery and replication in blood, brain and cerebrospinal fluid. Brain Communications, 5(1): fcac343. doi:10.1093/braincomms/fcac343. [PubMan] : Malpartida, A. B., Williamson, M., Narendra, D. P., Wade-Martins, R., & Ryan, B. J. (2021). Mitochondrial dysfunction and mitophagy in Parkinson's Disease: From mechanism to therapy. Trends in biochemical sciences, 46(4), 329-343. doi:10.1016/j.tibs.2020.11.007. [PubMan] : Forero, A., Ku, H.-P., Malpartida, A. B., Waeldchen, S., Alhama-Riba, J., Kulka, C., Aboagye, B., Norton, W. H. J., Young, A. M. J., Ding, Y.-Q., Blum, R., Sauer, M., Rivero, O., & Lesch, K.-P. (2020). Serotonin (5-HT) neuron-specific inactivation of Cadherin-13 impacts 5-HT system formation and cognitive function. Neuropharmacology, 168: 108018. doi:10.1016/j.neuropharm.2020.108018. [PubMan]